Renalytix AI (GB:RENX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Renalytix plc, a leader in AI-driven diagnostics for kidney health, saw its CEO, James McCullough, enhance his stake by purchasing 53,300 shares at £0.075 each, reflecting confidence in the company’s future. This move follows a similar purchase by COO Chris Scott, indicating strong insider belief in Renalytix’s growth potential.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
